Cellectis S.A.

As of June 30, 2026, Cellectis S.A. carries a market capitalization of 262.12M, placing it among publicly traded companies globally. Its enterprise value stands at 190.10M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cellectis S.A.'s next confirmed earnings release is scheduled for November 9, 2026.

As of June 30, 2026, Cellectis S.A. has 100.70M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 5.28, and the price-to-book ratio stands at 7.29.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.84 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 190.10M versus a market cap of 262.12M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Cellectis S.A. maintains a current ratio of 1.37, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 205.94, indicating elevated leverage, while an interest coverage ratio of -4.82 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Cellectis S.A. posted a negative return on equity (ROE) of -94.53, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -21.02, reflecting losses generated across the asset base. The company generates approximately 217,906.37 in revenue per employee across its workforce of 227.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Cellectis S.A. recorded an income tax benefit of -308,105.60 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -57.48M and -57.17M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Cellectis S.A.'s stock has declined approximately 69.31% over the past 52 weeks. The 50-day moving average sits at 1.88, while the 200-day moving average is 2.76.

Over the twelve months ended June 30, 2026, Cellectis S.A. generated 49.52M in revenue and converted that into -57.17M in net income, yielding earnings per share of -0.57. EBITDA reached -34.08M, while operating income came in at -50.77M.

As of June 30, 2026, Cellectis S.A. holds 146.04M in cash and equivalents against 74.03M in total debt, resulting in a net debt position of 16.09M. Total book value stands at 35.95M, with working capital of 43.29M providing operational flexibility.

Cellectis S.A. produced -36.43M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.93M in capital expenditures, free cash flow totaled -39.37M - equivalent to -0.39 per share.

Over the twelve months ended June 30, 2026, Cellectis S.A. posted a gross margin of 82.27, reflecting its pricing power and cost economics. The operating margin of -102.52 and net profit margin of -115.45 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Cellectis S.A. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -15.00: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 5.53, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Cellectis S.A. shareholders.

As of June 30, 2026, Cellectis S.A. has an Altman Z-Score of -1.09, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.